01The twelve checks
The same twelve rows as our supplier audit scorecard, where each row is scored 0, 1 or 2 with the red flags to look for.
The report names an independent testing lab, with its address, and that lab will confirm it issued the report.
A separate report for every lot, matched by lot number.
Purity by HPLC, with the percentage and the chromatogram trace.
Identity by mass spectrometry, with the observed mass next to the expected mass.
An endotoxin result with its units (EU/mg) and method (LAL or recombinant factor C).
The lot number printed on the vial label itself, matching the report.
A page or QR code for each lot where the report can be opened and checked against the lot number.
A named person with a science background who answers questions about methods and reports.
Stated conditions for transit and storage, and packaging that matches what is stated.
A plain outer box, and inside a full label: compound, contents in mg, lot and the research-use line.
Products described by what they are (sequence, identity, purity), with research-use terms, and education kept apart from listings.
Creators and affiliates label paid posts clearly, up front, and the seller says publicly that it pays them.
02Red flags that end the search
- Dosing charts, injection guides or “protocols” on a research-use site.
- Pens, syringes or “kits” sold alongside vials.
- The same COA image on several products.
- Purity claims above what the method can support, with no trace.
- Payment only by crypto or gift cards, and no company details.
03Why claims are a red flag, not a feature
A supplier that coaches human use is telling regulators its products are medicines. That puts the business, and its stock, at risk of enforcement. Regulators in the UK and EU have said they look past research-only labels when marketing points at people.
A supplier that stays strictly in the research lane is the one more likely to still be there, with the same lots, next year.